GeneDx Holdings Corp. (WGS)

NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-23

$56.15-16.37%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge GeneDx Holdings Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
Exome and genome revenue	$110M–$112M	—
Revenue	$122M–$124M	—
Gross margin	About 70%non-GAAP	—
FY 2026 · Q4
Revenue	—	142.64M
EPS	—	0.29
FY 2026 · Annual
Revenue	$475M–$490M	482.26M
EPS	—	0.1
Exome and genome revenue growth	At least 20%	—
Gross margin	About 70%non-GAAP	—
FY 2027 · Annual
Revenue	—	598.95M
EPS	—	1.199

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Growth in exome and genome revenue	New leadership and focus on exome and genome revenue support recovery.	Improving	exome and genome revenue growth stalls or declines next year	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Exome and genome test volume grew from 23,246 in 2025-Q2 to 30,785 in 2026-Q2 (32% YoY growth), and revenue grew from $86.0 million to $100.3 million (17% YoY growth). Management targets at least 30% volume growth and 20% revenue growth for 2026. The trajectory is delivering strong volume growth and solid revenue growth. Delivery assessment Oct 24, 2026
Gross margin near 70.5% by end of 2025	The company targets a gross margin near 70.5% and positive adjusted net income by year-end.	Improving	gross margin falls below 65% in FY25	Gross margin: 68.37% FY2026-Q2; GAAP. Published target: ~70.5%. Target period is not explicitly aligned with this observation. Source published Aug 3, 202668.365956 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8c17c2b6-b586-4126-a53e-96e6b395ce6c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve positive adjusted net income in 2026	The company targets a gross margin near 70.5% and positive adjusted net income by year-end.	Broken	adjusted net income remains negative through FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Adjusted net income improved from a loss of $8.2 million in 2026-Q1 to a positive $0.4 million in 2026-Q2, while GAAP net loss remains but adjusted results show progress. Management reiterated positive adjusted net income guidance for full year 2026. The trajectory is delivering with improving adjusted profitability. Delivery assessment Oct 24, 2026
Revenue reaches at least $475M in 2026	A primary condition in GeneDx Holdings Corp.'s published investment case. The stated target is >=475 USD_MILLIONS.	Intact	revenue falls below $475M in FY26	Revenue: $114.44M FY2026-Q2; GAAP. Published target: >=475 USD_MILLIONS. Target period is not explicitly aligned with this observation. Source published Aug 3, 2026114,440,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8c17c2b6-b586-4126-a53e-96e6b395ce6c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management updated full year 2026 revenue guidance downward from $540-$555 million in 2025-Q4 to $475-$490 million by 2026-Q1 and reiterated it in 2026-Q2. Revenue grew from $102.3 million in 2026-Q1 to $114.4 million in 2026-Q2. The trajectory matches management's updated guidance. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$1.10 → Unavailable · observed estimates

FY2027 revenue$0.60B

$0.59B → $0.60B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$1.10	$594,900,000	8 / 9
2026-07-25	$1.10	$594,900,000	8 / 9
2026-07-26	$1.10	$594,900,000	8 / 9
2026-07-27	$1.10	$594,900,000	8 / 9
2026-07-28	Unavailable	$594,167,211	4 / 6
2026-07-29	Unavailable	$594,167,211	4 / 6
2026-07-30	$1.10	$594,900,000	8 / 9
2026-07-31	Unavailable	$594,179,411	4 / 6
2026-08-01	Unavailable	$594,179,411	4 / 6
2026-08-02	$1.10	$594,900,000	8 / 9
2026-08-03	$1.10	$594,900,000	8 / 9
2026-08-04	Unavailable	$596,151,711	4 / 6
2026-08-05	$1.10	$594,900,000	8 / 9
2026-08-06	$1.12	$594,688,890	8 / 9
2026-08-08	$1.14	$594,688,890	8 / 9
2026-08-09	$1.14	$594,688,890	8 / 9
2026-08-10	$1.14	$594,688,890	8 / 9
2026-08-12	Unavailable	$596,622,222	4 / 6
2026-08-13	Unavailable	$596,622,222	4 / 6
2026-08-14	Unavailable	$596,622,222	4 / 6
2026-08-15	Unavailable	$596,622,222	4 / 6
2026-08-16	Unavailable	$596,622,222	4 / 6
2026-08-17	Unavailable	$596,622,222	4 / 6
2026-08-18	Unavailable	$596,622,222	4 / 6
2026-08-19	Unavailable	$596,622,222	4 / 6
2026-08-20	Unavailable	$598,544,444	4 / 6
2026-08-21	Unavailable	$598,544,444	4 / 6
2026-08-22	Unavailable	$598,544,444	4 / 6
2026-08-23	Unavailable	$598,544,444	4 / 6
2026-08-24	Unavailable	$598,544,444	4 / 6
2026-08-25	Unavailable	$598,544,444	4 / 6
2026-08-26	Unavailable	$598,544,444	4 / 6
2026-08-27	Unavailable	$598,544,444	4 / 6
2026-08-28	Unavailable	$598,544,444	4 / 6
2026-08-29	Unavailable	$598,544,444	4 / 6
2026-08-30	Unavailable	$598,544,444	4 / 6
2026-08-31	Unavailable	$598,544,444	4 / 6
2026-09-01	Unavailable	$598,544,444	4 / 6
2026-09-02	Unavailable	$598,544,444	4 / 6
2026-09-03	Unavailable	$598,544,444	4 / 6
2026-09-04	Unavailable	$598,544,444	4 / 6
2026-09-05	Unavailable	$598,544,444	4 / 6
2026-09-06	Unavailable	$598,544,444	4 / 6
2026-09-07	Unavailable	$598,544,444	4 / 6
2026-09-08	Unavailable	$598,544,444	4 / 6
2026-09-09	Unavailable	$598,544,444	4 / 6
2026-09-10	Unavailable	$598,544,444	4 / 6
2026-09-11	Unavailable	$598,544,444	4 / 6
2026-09-12	Unavailable	$598,544,444	4 / 6
2026-09-13	Unavailable	$598,544,444	4 / 6
2026-09-14	Unavailable	$598,544,444	4 / 6
2026-09-15	Unavailable	$598,544,444	4 / 6
2026-09-16	Unavailable	$598,544,444	4 / 6
2026-09-17	Unavailable	$598,544,444	4 / 6
2026-09-18	Unavailable	$598,544,444	4 / 6
2026-09-19	Unavailable	$598,544,444	4 / 6
2026-09-20	Unavailable	$598,544,444	4 / 6
2026-09-21	Unavailable	$598,544,444	4 / 6
2026-09-22	Unavailable	$598,544,444	4 / 6
2026-09-23	Unavailable	$598,511,111	4 / 6
2026-09-24	Unavailable	$598,511,111	4 / 6
2026-09-25	Unavailable	$598,511,111	4 / 6
2026-09-26	Unavailable	$598,511,111	4 / 6
2026-09-27	Unavailable	$598,511,111	4 / 6
2026-09-28	Unavailable	$598,511,111	4 / 6
2026-09-29	Unavailable	$598,511,111	4 / 6
2026-09-30	Unavailable	$598,511,111	4 / 6
2026-10-01	Unavailable	$598,925,000	4 / 6
2026-10-02	Unavailable	$598,925,000	4 / 5
2026-10-03	Unavailable	$598,925,000	4 / 5
2026-10-04	Unavailable	$598,925,000	4 / 5
2026-10-05	Unavailable	$598,925,000	4 / 5
2026-10-06	Unavailable	$598,925,000	4 / 5
2026-10-07	Unavailable	$598,925,000	4 / 5
2026-10-08	Unavailable	$598,925,000	4 / 5
2026-10-09	Unavailable	$598,925,000	4 / 5
2026-10-10	Unavailable	$598,925,000	4 / 5
2026-10-11	Unavailable	$598,925,000	4 / 5
2026-10-12	Unavailable	$598,925,000	4 / 5
2026-10-13	Unavailable	$598,925,000	4 / 5
2026-10-14	Unavailable	$598,925,000	4 / 5
2026-10-15	Unavailable	$598,925,000	4 / 5
2026-10-16	Unavailable	$598,925,000	4 / 5
2026-10-17	Unavailable	$598,925,000	4 / 5
2026-10-18	Unavailable	$598,925,000	4 / 5
2026-10-19	Unavailable	$598,925,000	4 / 5
2026-10-20	Unavailable	$598,950,000	4 / 5
2026-10-21	Unavailable	$598,950,000	4 / 5
2026-10-22	Unavailable	$598,950,000	4 / 5
2026-10-23	Unavailable	$598,950,000	4 / 5
2026-10-24	Unavailable	$598,950,000	4 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	9	0	0
2026-06-01	9	0	0
2026-07-01	9	0	0
2026-08-01	9	0	0
2026-09-01	9	0	0
2026-10-01	8	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

GuggenheimOct 1 · prior Jun 29

$74.00 → $83.00+12.2%

$0$45.65$91.30

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Growth in exome and genome revenueQualitative condition
Gross margin near 70.5% by end of 2025Gross margin: 68.37%
Achieve positive adjusted net income in 2026Published status: Broken
Revenue reaches at least $475M in 2026Revenue: $114.44M

Next proof point

Oct 27, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.2%Typical daily move · historical

Downside history

-79.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

GeneDx Holdings Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth business rather than a proven durable compounder, because it remains loss-making and recent financial performance is weak. The multi-year thesis is in a watch state: execution is showing progress, but elevated risk and results below the industry cohort keep confidence limited.

What's priced into GeneDx Holdings Corp.

WGS is described as cheap versus peers, while the model’s expectations gap is slightly negative and its confidence is low. The evidence does not show that the valuation is fragile, but it also does not establish that current expectations leave much room for execution setbacks.

What the fundamentals likely do

Near term, revenue guidance is lower than it was in late 2025, though management has reiterated its current 2026 range and second-quarter revenue increased from the first quarter. Exome and genome test volumes are growing strongly, and adjusted net income moved from a loss in the first quarter to a small profit in the second, while GAAP results remain loss-making. Erratic earnings surprises and a downward trend in surprises remain risks, despite a recent earnings beat.

What GeneDx Holdings Corp. hinges on

The multi-year thesis depends on WGS sustaining test-volume growth, converting that growth into revenue, and reaching positive adjusted net income for 2026. A guidance cut or further weakening in jobs data could weigh on the near-term business outlook, while continued strong results from healthcare sector bellwethers could support the sector backdrop.